



DRUG DISCOVERY

# Targeted protein degradation platform



# Our targeted protein degradation platform

**With decades of expertise in drug discovery combined with our cutting-edge degradation platform, we provide innovative strategies for rapid discovery of PROTACs and molecular glues across all business models including consulting, degrader library synthesis and integrated projects from conception to success.**



## **Flexible starting point:**

Optimisation of client's already existing POI- and/or E3 ligase-binders or the discovery of entirely new POI- and/or E3 ligase-binders. World class protein sciences and biophysics teams to unlock even the most difficult targets.

## **Various end point:**

With our smart design and multi-parameter optimisation strategy, we provide the clients with advanced compounds to reach any milestone in the preclinical pipeline and with high-quality data packages.

## **Tailor-made solution:**

With focused library design, state-of-the-art synthesis methods and direct-to biology approaches, we offer the most suitable solution for your project with significantly reduced cycle time.

## **Client-centered and goal-oriented team:**

We are expert drug hunters and problem-solving enthusiasts with a collaborative mindset. We share your sense of urgency to deliver high-quality compounds/candidates.


# Targeted protein degradation platform for your drug discovery program




## PROTACS AND GLUES SMART DESIGN

Innovative design platform combined with prediction tools and historical data streamline the prioritisation of compounds for synthesis.

- Data mining
- Warhead design: Scaffold hopping, pharmacophore-based docking
- De novo linker design (LINK-invent) and structure-based linker optimisation
- Prediction tool (e.g., for ternary complex prediction, solubility or permeability)
- End-to-end degrader design.





## BUILDING BLOCKS AND LINKERS

Ready-to-use collection of linkers and E3 binders helps increase the efficiency of synthesis of degraders.

- Structurally highly diverse set of linkers and E3 binders
- Current library consists of >20 ligands for E3 ligases, >9k linkers and >100 precursors ready to conjugate with POI binder
- Continuously growing.



## MULTI-PARAMETER OPTIMISATION

Data generation and data analysis using modern visualisation tools result in data-driven design and prioritisation of compounds

- Optimise PK/PD parameters and safety properties by smart design and linkerology to provide candidates appropriate for the designated routes of administration
- Smart design and linkerology
- A robust screening tree, combined with reduced cycle times enable rapid generation of data to support further design.



## EFFICIENT SYNTHESIS AND DIRECT-TO-BIOLOGY

State of the art parallel synthesis and assay technology ensure a direct-to-biology approach to accelerate the project significantly.

- Parallel synthesis with and without solid-phase-supported synthesis
- Plate-based chemistry and pool synthesis: Compounds can be tested without prior purification
- 100+ degraders per day by parallel synthesis, pool synthesis and plate-based chemistry
- Direct-to-Biology assays: SPR, ASMS, HiBiT and others.




## PURIFICATION AND ANALYTICAL SERVICES

In-house purification and analytics services to support your project or can be added as a standalone service.

- Specialised NMR measurements (up to 600 MHz NMR with cryo-probe)
- Structure elucidation by experts and certificates of analysis
- Dedicated high-throughput purification lab from mg to g scales and chiral separation expertise (e.g. SFC, chiral phases)
- Determination of PhysChem parameters (e.g. EPSA, ChromLogD 7.4, solubility, lipophilicity, stability, crystallinity).

FOLLOW US



# THE SCIENCE CRO

YOUR PARTNER OF  
CHOICE IN BRINGING  
THERAPEUTICS TO LIFE


**Nuvisan is a full-service contract research organisation (CRO) and development and manufacturing organisation (CDMO) with state-of-the-art laboratories in Germany and France.**

Our pharmaceutical, biotechnology, venture capital and non-profit clients partner with us because our high-quality end-to-end solutions and scientific expertise enable us to streamline and accelerate drug discovery and development – from ensuring target understanding to helping bring therapeutics to life.

Founded over 40 years ago by a team of pharma industry innovators, Nuvisan has established a reputation for expertise and professionalism.

Our team leaders have extensive experience in the biopharma industry, and our unique centres of excellence – for drug discovery in Berlin, formulation and GMP manufacturing in Sophia Antipolis, and our bioanalysis hub in Neu-Ulm – enable our experienced scientists to help guide and advance projects.

We know how to discover, develop and bring the next generation of medicines to market. At the same time, we are committed to flexibility, transparency and collaboration in our approach, working closely with you to adapt to your individual needs, minimise risks and help deliver your project.



## Contact us

**NUVISAN**

Nuvisan  
Muellerstrasse 178  
13353 Berlin  
Germany

hello@nuvisan.com  
+49 731 9840 - 0

[nuvisan.com](https://www.nuvisan.com)